| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,030 |
11,297 |
$519K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,063 |
2,739 |
$248K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,401 |
4,009 |
$139K |
| 20610 |
|
658 |
555 |
$22K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,017 |
888 |
$11K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
724 |
621 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
793 |
699 |
$500.62 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
25 |
23 |
$170.75 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
42 |
36 |
$33.93 |
| 3074F |
|
389 |
345 |
$1.60 |
| 3079F |
|
213 |
189 |
$0.83 |
| 3078F |
|
163 |
140 |
$0.54 |
| 3080F |
|
99 |
81 |
$0.32 |
| 3077F |
|
68 |
62 |
$0.24 |
| 3075F |
|
50 |
41 |
$0.17 |
| 1170F |
|
41 |
28 |
$0.11 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
2,036 |
1,692 |
$0.01 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
928 |
776 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
211 |
174 |
$0.00 |
| M1003 |
Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy |
225 |
184 |
$0.00 |
| 3471F |
|
172 |
140 |
$0.00 |
| M1007 |
>=50% of total number of a patient's outpatient ra encounters assessed |
415 |
339 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
104 |
81 |
$0.00 |
| G2112 |
Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months |
239 |
202 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
5,340 |
4,547 |
$0.00 |
| 3472F |
|
14 |
12 |
$0.00 |
| 4192F |
|
163 |
125 |
$0.00 |
| 3470F |
|
45 |
36 |
$0.00 |
| G8399 |
Patient with documented results of a central dual-energy x-ray absorptiometry (dxa) ever being performed |
17 |
12 |
$0.00 |